XTL Biopharmaceutica Stock Forward View - Triple Exponential Smoothing

XTLB Stock  USD 0.61  0.02  3.64%   
This reference view applies Triple Exponential Smoothing to XTL Biopharmaceuticals Ltd's historical closing prices. XTL Biopharmaceuticals Ltd's Triple Exponential Smoothing reference page summarizes the forecasted price and model accuracy metrics from daily trading data. XTL Biopharmaceuticals Ltd's forecast reference data is generated from the equity's historical trading prices. Mean absolute deviation and related metrics help quantify forecast uncertainty for XTL Biopharmaceuticals Ltd.
The Triple Exponential Smoothing forecasted value of XTL Biopharmaceuticals Ltd on the next trading day is expected to be 0.60 with a mean absolute deviation of 0.04 and the sum of the absolute errors of 2.64.As with simple exponential smoothing, in triple exponential smoothing models past XTL Biopharmaceutica observations are given exponentially smaller weights as the observations get older. In other words, recent observations are given relatively more weight in forecasting than the older XTL Biopharmaceuticals Ltd observations. All forecast values on this page for XTL Biopharmaceuticals Ltd are Triple Exponential Smoothing reference data derived from historical price series.
Triple exponential smoothing for XTL Biopharmaceutica - also known as the Winters method - is a refinement of the popular double exponential smoothing model with the addition of periodicity (seasonality) component. Simple exponential smoothing technique works best with data where there are no trend or seasonality components to the data. When XTL Biopharmaceutica prices exhibit either an increasing or decreasing trend over time, simple exponential smoothing forecasts tend to lag behind observations. Double exponential smoothing is designed to address this type of data series by taking into account any trend in XTL Biopharmaceutica price movement. However, neither of these exponential smoothing models address any seasonality of XTL Biopharmaceuticals.

Triple Exponential Smoothing Price Forecast For the 25th of March

Given 90 days horizon, the Triple Exponential Smoothing forecasted value of XTL Biopharmaceuticals Ltd on the next trading day is expected to be 0.60 with a mean absolute deviation of 0.04 , mean absolute percentage error of 0.01 , and the sum of the absolute errors of 2.64 .
Please note that although there have been many attempts to predict XTL Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that XTL Biopharmaceutica's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).

Stock Forecast Pattern

Backtest XTL Biopharmaceutica  XTL Biopharmaceutica Price Prediction  Research Analysis  

Forecasted Value

Forecasting XTL Biopharmaceuticals Ltd for the next session involves measuring the model's historical ability to define credible downside and upside scenarios. The projected forecast band currently runs from roughly 0.01 on the downside to about 10.53 on the upside.
Market Value
0.61
0.60
Expected Value
10.53
Upside

Model Predictive Factors

The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of XTL Biopharmaceutica stock data series using in forecasting. Note that when a statistical model is used to represent XTL Biopharmaceutica stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.
AICAkaike Information CriteriaHuge
BiasArithmetic mean of the errors -0.0079
MADMean absolute deviation0.0448
MAPEMean absolute percentage error0.0541
SAESum of the absolute errors2.645
As with simple exponential smoothing, in triple exponential smoothing models past XTL Biopharmaceutica observations are given exponentially smaller weights as the observations get older. In other words, recent observations are given relatively more weight in forecasting than the older XTL Biopharmaceuticals Ltd observations.

Other Forecasting Options for XTL Biopharmaceutica

Volume-weighted price analysis for XTL Stock gives heavier weight to price levels where trading activity was highest. Crossovers in the MACD line and signal line can identify shifts in XTL momentum before they appear in raw price. Comparing XTL Biopharmaceutica's realized volatility to implied volatility reveals whether the options market expects larger or smaller moves. Readings above 80 or below 20 highlight potential reversal zones in XTL Stock price action.

XTL Biopharmaceutica Related Equities

Investors studying XTL Biopharmaceutica often look at related stocks within the Health Care space to gauge pricing and results. Peer review on balance sheet metrics shows how XTL Biopharmaceutica's capital structure stacks up against similar firms. When XTL Biopharmaceutica breaks from its peer group on a key metric, it often signals a firm-level change worth exploring.
 Risk & Return  Correlation

XTL Biopharmaceutica Market Strength Events

Evaluating the market strength of XTL Biopharmaceutica stock allows investors to gauge shifts in market momentum. Monitoring these indicators highlights periods where XTL Biopharmaceuticals Ltd trading conditions shift meaningfully. These metrics are particularly useful when XTL Biopharmaceutica stock shows divergence from broader market trends. Regularly reviewing XTL Biopharmaceuticals Ltd strength signals helps maintain a structured approach to position management.

XTL Biopharmaceutica Risk Indicators

Understanding XTL Biopharmaceutica's risk indicators is essential for any investor seeking to forecast its future price accurately. By identifying how much risk is embedded in XTL Biopharmaceutica's investment, investors can decide how to position their exposure. Reviewing XTL Biopharmaceutica's basic risk indicators is essential for managing investment risk effectively. The risk-return trade-off for xtl stock becomes clearer when XTL Biopharmaceutica's risk indicators are properly assessed.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.

Story Coverage note for XTL Biopharmaceutica

A coverage review of XTL Biopharmaceuticals Ltd shows when the security is attracting above-average attention from contributors and market observers. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.

XTL Biopharmaceutica Short Properties

Short-interest signals around XTL Biopharmaceuticals Ltd can help investors judge whether skeptical positioning is starting to pressure price predictability and market tone. The practical goal is to identify when the balance between long and short participation may be changing the quality of the setup.
Common Stock Shares Outstanding1.8 M
Cash And Short Term Investments1.1 M

More Resources for XTL Stock Analysis

A broader look at XTL Biopharmaceuticals comes from its financial reports and historical data. These indicators describe how financial results are generated.